Company: VCYT
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001384101-25-000130
Chunk: 101

Company: VERACYTE, INC.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 8
Chunk 101
---
 offerings, trade names and customer relationships.

Other Income (Loss), Net

Other income (loss), net consists primarily of interest income from our cash held in interest bearing accounts, realized and unrealized gains and losses on foreign currency transactions and loss on the deconsolidation of Veracyte SAS.

27

Results of Operations

Comparison of the three and nine months ended September 30, 2025 and 2024 (in thousands of dollars, except percentages and test volume):

 Three Months Ended September 30,Nine Months Ended September 30, 20252024Change%20252024Change%Revenue:        Testing revenue$127,756 $109,536 $18,220 17%$357,328 $306,809 $50,519 16%Product revenue3,301 3,188 113 4%10,479 10,631 (152)(1)%Biopharmaceutical and other revenue815 3,136 (2,321)(74)%8,702 9,692 (990)(10)%Total revenue131,872 115,860 16,012 14%376,509 327,132 49,377 15%Cost of revenue:    Cost of testing revenue33,777 29,029 4,748 16%94,444 82,928 11,516 14%Cost of product revenue3,015 1,792 1,223 68%6,186 6,310 (124)(2)%Cost of biopharmaceutical and other revenue1,091 3,112 (2,021)(65)%7,361 9,762 (2,401)(25)%Intangible asset amortization - cost of revenue2,707 2,917 (210)(7)%7,959 8,741 (782)(9)%Total cost of revenue40,590 36,850 3,740 10%115,950 107,741 8,209 8%Gross profit91,282 79,010 12,272 16%260,559 219,391 41,168 19%Operating expenses:Research and development15,981 17,574 (1,593)(9)%49,965 50,004 (39)—%Selling and marketing24,455 22,612 1,843 8%74,